Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Duchenne Muscular Dystrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Arkansas Children's Hospital, Little Rock, Arkansas, United States
Contact: Study coordinator (Aravindhan Veerapandiyan, Dr) · aveerapandiyan@uams.edu · 501-364-1850
Contact: Principal Investigator (Aravindhan Veerapandiyan, Dr)
Rare Disease Research LLC, Atlanta, Georgia, United States
Contact: Study coordinator (Scott Batchelor, Dr) · sbatchelor@rarediseaseresearch.com · 404-782-8239
Contact: Principal Investigator (Scott Batchelor, Dr)
Istiklal Hospital/ Clinical Research Unit, Amman, Jordan
Contact: Study coordinator (Muath Alqurashi, Dr) · drmuathalqurashi@yahoo.com
Contact: Principal Investigator (Muath Alqurashi, Dr)
The Specialty Hospital (TSH)/ Advanced Clinical Center, Amman, Jordan
Contact: Study coordinator (Mai Bader, Dr) · dr.mai.bader@hotmail.com
Contact: Principal Investigator (Mai Bader, Dr)
Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, United Kingdom
Contact: Study coordinator (Laurent Servais, MD, PhD) · Laurent.Servais@ouh.nhs.uk · 01865 227503
Contact: Principal Investigator (Laurent Servais, MD, PhD)

Study leads

Medical Director, MD
Study Director
Wave Life Sciences

View source on ClinicalTrials.gov Contact study team (email)